The immunogenicity of mAbs is a significant safety issue, however the predictivity of animal choices for evaluation of immunogenicity is low as clearly stated in the recent EMEA guideline over the immunogenicity assessment of biotechnology-derived therapeutic proteins.52 Apart from evaluating closely related products (e.g., biosimilars), obtainable pet choices can’t be likely to provide relevant information […]